Literature DB >> 1919612

Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases.

W Oder1, G Grimm, H Kollegger, P Ferenci, B Schneider, L Deecke.   

Abstract

Forty-five patients with Wilson's disease (WD) were prospectively studied: 27 had neurological deficits, 12 hepatic signs, and 6 were asymptomatic. Kayser-Fleischer rings occurred in 23 of the neurological patients and in only 4 of the hepatic patients. Neurological features were extremely variable with respect to frequency and severity. Most frequent were dysdiadochokinesis (25 patients), dysarthria (23), bradykinesia (17), and posture tremor (14). Fifteen, mainly long-term treated patients, presented with rather discrete neurological abnormalities which predominantly consisted of dysarthria and various forms of tremor. Eight patients had a parkinsonian type of neurological WD associated with signs of an organic mood syndrome. Three patients were predominantly hyperkinetic, presenting with dystonic and choreatic movements. In 1 patient, ataxia was the predominant neurological feature. There was a clear-cut correlation between the severity of neurological impairment and the restriction in functional capacity. Nine patients were not able to engage in salaried employment or were retired. Psychiatric symptoms and behavioural disorders were common, varying from mild personality and psychological disturbances to severe psychiatric illness resembling psychotic disorders and major depressive syndromes. Significant mental deterioration was not found in the patients. Disturbances of mood were observed in 12 patients, all of whom had neurological abnormalities. There was a history of an attempted suicide in 7 patients, and a history of an organic delusional syndrome in 3.

Entities:  

Mesh:

Year:  1991        PMID: 1919612     DOI: 10.1007/bf00319740

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  41 in total

1.  Studies on hepatocerebral disease. III. Hepatolenticular degeneration in Japan, with studies on copper metabolism.

Authors:  S OKINAKA
Journal:  Neurology       Date:  1961-09       Impact factor: 9.910

2.  Penicillamine, a new oral therapy for Wilson's disease.

Authors:  J M WALSHE
Journal:  Am J Med       Date:  1956-10       Impact factor: 4.965

3.  Wilson's disease. Clinical and laboratory maniestations in 40 patients.

Authors:  G T Strickland; M L Leu
Journal:  Medicine (Baltimore)       Date:  1975-03       Impact factor: 1.889

Review 4.  Wilson's disease: yesterday, today, and tomorrow.

Authors:  J M Walshe
Journal:  Mov Disord       Date:  1988       Impact factor: 10.338

5.  [Nature of course and rehabilitation in the clinical stage of Wilson's disease].

Authors:  J Lössner; B Eichner; H Bachmann; D Biesold; K Günther
Journal:  Psychiatr Neurol Med Psychol (Leipz)       Date:  1974-11

6.  Wilson's disease in India. I. Geographic, genetic, and clinical aspects in 16 families.

Authors:  D K Dastur; D K Manghani; N H Wadia
Journal:  Neurology       Date:  1968-01       Impact factor: 9.910

Review 7.  Wilson's disease and epilepsy.

Authors:  T R Dening; G E Berrios; J M Walshe
Journal:  Brain       Date:  1988-10       Impact factor: 13.501

8.  Penicillamine therapy for schizophreniform psychosis in Wilson's disease.

Authors:  I Modai; L Karp; U A Liberman; H Munitz
Journal:  J Nerv Ment Dis       Date:  1985-11       Impact factor: 2.254

9.  Neurological abnormalities in Wilson's disease are reversible.

Authors:  S Lingam; J Wilson; H Nazer; A P Mowat
Journal:  Neuropediatrics       Date:  1987-02       Impact factor: 1.947

10.  [Acoustically evoked brain stem potential in Wilson disease].

Authors:  T Krause; W P Pankau; A Wagner; J Lössner
Journal:  Psychiatr Neurol Med Psychol (Leipz)       Date:  1984-09
View more
  30 in total

1.  Serial diffusion-weighted MRI in a case of Wilson's disease with acute onset hemichorea.

Authors:  Nobutoshi Kawamura; Yasumasa Ohyagi; Masakazu Kawajiri; Takashi Yoshiura; Futoshi Mihara; Hirokazu Furuya; Jun-ichi Kira
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

2.  Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding.

Authors:  W Oder; T Brücke; H Kollegger; J Spatt; S Asenbaum; L Deecke
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 3.  Challenges in the diagnosis of Wilson disease.

Authors:  Aurélia Poujois; France Woimant
Journal:  Ann Transl Med       Date:  2019-04

4.  Molecular pathogenesis of Wilson disease: haplotype analysis, detection of prevalent mutations and genotype-phenotype correlation in Indian patients.

Authors:  A Gupta; D Aikath; R Neogi; S Datta; K Basu; B Maity; R Trivedi; J Ray; S K Das; P K Gangopadhyay; K Ray
Journal:  Hum Genet       Date:  2005-10-28       Impact factor: 4.132

5.  Complex psychiatric presentation in adolescent onset Wilson's disease.

Authors:  S Woerwag-Mehta; Peter Hindley; Tammy Hedderly; Anil Dhawan
Journal:  BMJ Case Rep       Date:  2011-01-11

Review 6.  Diagnosis and treatment of Wilson's disease.

Authors:  Indu Subramanian; Zeba F Vanek; Jeff M Bronstein
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 7.  Wilson disease.

Authors:  Reinhard Kitzberger; Christian Madl; Peter Ferenci
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

8.  [44-year-old patient with fulminant liver failure].

Authors:  A Kerber; C Sarrazin; C Allers; B Markus; K Engels; W Caspary; S Zeuzem
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

9.  Psychiatric manifestations of Wilson's disease and treatment with electroconvulsive therapy.

Authors:  Manoj Kumar Sahoo; Ajit Avasthi; Madhusmita Sahoo; Manish Modi; Parthasarathy Biswas
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

10.  Relationship between striatal glucose consumption and copper excretion in patients with Wilson's disease treated with D-penicillamine.

Authors:  H Hefter; T Kuwert; H Herzog; G Arendt; W Stremmel; L E Feinendegen
Journal:  J Neurol       Date:  1993-11       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.